271 related articles for article (PubMed ID: 26922744)
1. Signaling Pathways and Emerging Therapies in Multiple Myeloma.
Ramakrishnan V; D'Souza A
Curr Hematol Malig Rep; 2016 Apr; 11(2):156-64. PubMed ID: 26922744
[TBL] [Abstract][Full Text] [Related]
2. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.
Ramakrishnan V; Kumar S
Leuk Lymphoma; 2018 Nov; 59(11):2524-2534. PubMed ID: 29322846
[TBL] [Abstract][Full Text] [Related]
3. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments.
Hu J; Hu WX
Cancer Lett; 2018 Feb; 414():214-221. PubMed ID: 29174802
[TBL] [Abstract][Full Text] [Related]
4. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.
Harvey RD; Lonial S
Future Oncol; 2007 Dec; 3(6):639-47. PubMed ID: 18041916
[TBL] [Abstract][Full Text] [Related]
5. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
6. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
Quesada AE; Nguyen ND; Rios A; Brown RE
Int J Clin Exp Pathol; 2014; 7(12):8732-9. PubMed ID: 25674239
[TBL] [Abstract][Full Text] [Related]
7. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS; Mitsiades N; Poulaki V; Schlossman R; Akiyama M; Chauhan D; Hideshima T; Treon SP; Munshi NC; Richardson PG; Anderson KC
Oncogene; 2002 Aug; 21(37):5673-83. PubMed ID: 12173037
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
9. Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation.
Bai C; Yang X; Zou K; He H; Wang J; Qin H; Yu X; Liu C; Zheng J; Cheng F; Chen J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):573-84. PubMed ID: 26935715
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of multiple myeloma cell proliferation by ginsenoside Rg3 via reduction in the secretion of IGF-1.
Li Y; Yang T; Li J; Hao HL; Wang SY; Yang J; Luo JM
Mol Med Rep; 2016 Sep; 14(3):2222-30. PubMed ID: 27430248
[TBL] [Abstract][Full Text] [Related]
12. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):16-34. PubMed ID: 23534949
[TBL] [Abstract][Full Text] [Related]
13. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.
Vrábel D; Pour L; Ševčíková S
Blood Rev; 2019 Mar; 34():56-66. PubMed ID: 30501907
[TBL] [Abstract][Full Text] [Related]
14. Novel conjugates of endoperoxide and 4-anilinoquinazoline induce myeloma cell apoptosis by inhibiting the IGF1-R/AKT/mTOR signaling pathway.
Xu Y; Zeng K; Wang X; Zhang J; Cao B; Zhang Z; Qiao C; Xu X; Wang Q; Zeng Y; Mao X
Biosci Trends; 2020 May; 14(2):96-103. PubMed ID: 32173687
[TBL] [Abstract][Full Text] [Related]
15. The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma.
Li J; Zhu J; Cao B; Mao X
Curr Pharm Des; 2014; 20(1):125-35. PubMed ID: 24001224
[TBL] [Abstract][Full Text] [Related]
16. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Podar K; Richardson PG; Chauhan D; Anderson KC
Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
[TBL] [Abstract][Full Text] [Related]
17. Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma.
Kudo C; Yamakoshi H; Sato A; Ohori H; Ishioka C; Iwabuchi Y; Shibata H
Anticancer Res; 2011 Nov; 31(11):3719-26. PubMed ID: 22110192
[TBL] [Abstract][Full Text] [Related]
18. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex signaling axis in adenoid cystic carcinoma.
Sun ZJ; Chen G; Zhang W; Hu X; Liu Y; Zhou Q; Zhu LX; Zhao YF
Mol Pharmacol; 2011 Jan; 79(1):106-18. PubMed ID: 20959361
[TBL] [Abstract][Full Text] [Related]
19. EEN regulates the proliferation and survival of multiple myeloma cells by potentiating IGF-1 secretion.
Huang EW; Xue SJ; Li XY; Xu SW; Cheng JD; Zheng JX; Shi H; Lv GL; Li ZG; Li Y; Liu CH; Chen XH; Liu H; Li J; Liu C
Biochem Biophys Res Commun; 2014 May; 447(2):271-7. PubMed ID: 24704450
[TBL] [Abstract][Full Text] [Related]
20. Bidirectional regulation of nuclear factor-κB and mammalian target of rapamycin signaling functionally links Bnip3 gene repression and cell survival of ventricular myocytes.
Dhingra R; Gang H; Wang Y; Biala AK; Aviv Y; Margulets V; Tee A; Kirshenbaum LA
Circ Heart Fail; 2013 Mar; 6(2):335-43. PubMed ID: 23395931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
